PROGNOSTIC METHOD FOR CHECKING EFFICACY OF MICRO RNA-122 INHIBITORS IN HCV+ PATIENTS

The present invention relates to the treatment of subjects infected with HCV which have been identified as likely responders to HCV therapy with a miR-122 inhibitor. The invention also provides for prognostic methods for determining the suitability of treatment of hepatitis C infection with an anti-...

Full description

Saved in:
Bibliographic Details
Main Authors PETRI, ANDREAS, KAUPPINEN, SAKARI, LINDOW, MORTEN, HAGEDORN, PETER
Format Patent
LanguageEnglish
French
German
Published 26.10.2016
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS OR TEST PAPERS THEREFOR
CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES
ENZYMOLOGY
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES
MEASURING
MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS
METALLURGY
MICROBIOLOGY
MUTATION OR GENETIC ENGINEERING
PHYSICS
PROCESSES OF PREPARING SUCH COMPOSITIONS
SPIRITS
TESTING
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:The present invention relates to the treatment of subjects infected with HCV which have been identified as likely responders to HCV therapy with a miR-122 inhibitor. The invention also provides for prognostic methods for determining the suitability of treatment of hepatitis C infection with an anti-HCV agent such as a miR-122 inhibitor.
Bibliography:Application Number: EP20120784565